Trexquant Investment LP Sells 81,751 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)

Trexquant Investment LP cut its stake in shares of Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 54.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 67,934 shares of the company's stock after selling 81,751 shares during the period. Trexquant Investment LP owned approximately 0.07% of Scholar Rock worth $2,936,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. GAMMA Investing LLC raised its holdings in Scholar Rock by 51.8% during the 4th quarter. GAMMA Investing LLC now owns 788 shares of the company's stock worth $34,000 after buying an additional 269 shares during the period. Quarry LP increased its position in shares of Scholar Rock by 3,443.3% in the third quarter. Quarry LP now owns 4,500 shares of the company's stock worth $36,000 after acquiring an additional 4,373 shares in the last quarter. Global Retirement Partners LLC raised its holdings in shares of Scholar Rock by 584.7% during the fourth quarter. Global Retirement Partners LLC now owns 897 shares of the company's stock valued at $39,000 after acquiring an additional 766 shares during the period. Nisa Investment Advisors LLC lifted its position in shares of Scholar Rock by 1,321.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company's stock valued at $48,000 after acquiring an additional 1,031 shares in the last quarter. Finally, Amalgamated Bank lifted its position in shares of Scholar Rock by 30.6% in the 4th quarter. Amalgamated Bank now owns 2,643 shares of the company's stock valued at $114,000 after acquiring an additional 620 shares in the last quarter. 91.08% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Scholar Rock

In other Scholar Rock news, insider Jing L. Marantz sold 5,655 shares of the business's stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $44.20, for a total transaction of $249,951.00. Following the completion of the sale, the insider now directly owns 67,200 shares of the company's stock, valued at approximately $2,970,240. The trade was a 7.76 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Tracey Sacco sold 6,500 shares of the firm's stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $33.08, for a total transaction of $215,020.00. Following the completion of the transaction, the insider now directly owns 71,750 shares in the company, valued at $2,373,490. This trade represents a 8.31 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 299,772 shares of company stock valued at $11,245,798 in the last three months. Corporate insiders own 19.20% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Wedbush reiterated an "outperform" rating and set a $50.00 price objective on shares of Scholar Rock in a research report on Tuesday, March 25th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $42.67.

Scholar Rock Price Performance

Shares of SRRK stock traded up $1.69 during mid-day trading on Friday, reaching $28.00. The company's stock had a trading volume of 1,761,907 shares, compared to its average volume of 1,215,842. The company has a market cap of $2.65 billion, a P/E ratio of -11.91 and a beta of 0.56. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. Scholar Rock Holding Co. has a 1-year low of $6.76 and a 1-year high of $46.98. The firm's 50-day moving average is $34.21 and its two-hundred day moving average is $34.51.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.